Around 5–7% of patients with advanced non-small cell lung cancer (NSCLC) carry an anaplastic lymphoma kinase (ALK) gene fusion, and younger, non-smoking female patients are primarily affected [1]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.